Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,67 USD | -12,17% | +11,72% | -60,36% |
Omzet 2024 * | 25,22 mln. 23,59 mln. | Omzet 2025 * | 32,65 mln. 30,54 mln. | Marktkapitalisatie | 3,95 mln. 3,7 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -24 mln. -22,45 mln. | Nettowinst (verlies) 2025 * | -9 mln. -8,42 mln. | EV/omzet 2024 * | 0,16 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,12 x |
K/w-verhouding 2024 * |
-0,17
x | K/w-verhouding 2025 * |
-0,74
x | Werknemers | 25 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,21% |
Recentste transcriptie over Eiger BioPharmaceuticals, Inc.
1 dag | -12,17% | ||
1 week | +11,72% | ||
Lopende maand | -46,65% | ||
1 maand | -50,23% | ||
3 maanden | -54,59% | ||
6 maanden | -60,96% | ||
Lopend jaar | -60,36% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 14-06-17 |
Director of Finance/CFO | 58 | 13-04-23 | |
James Vollins
CMP | Compliance Officer | 55 | 13-04-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 57 | 18-07-22 | |
Thomas Dietz
CHM | Chairman | 60 | 22-03-16 |
David Apelian
CEO | Chief Executive Officer | 59 | 14-06-17 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.03% | 0 M€ | 0,00% | - | |
0.00% | 18 M€ | +3,86% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 2,67 | -12,17% | 18 908 |
25-04-24 | 3,04 | -19,95% | 17 019 |
24-04-24 | 3,798 | -3,86% | 14 300 |
23-04-24 | 3,95 | -1,25% | 28 020 |
22-04-24 | 4 | +67,36% | 78 021 |
uitgestelde koers OTC Markets, 26 april 2024 om 21:59 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-60,36% | 3,95 mln. | |
+1,51% | 42,75 mld. | |
+8,57% | 41,34 mld. | |
+49,22% | 41,61 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |